sellWeak cluster of 510b5-1 plan
Ullem Scott B. sold $806k of EW
CVP, Chief Financial Officer at Edwards Lifesciences Corp. 11,250 shares at an average of $71.68, traded Dec 9, 2024, filed Dec 9, 2024.
Warning score
34Value
$806k
11,250 shares
Holdings after
30,561
-27% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001225208-24-010647, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | MOption exercise Common Stock10b5-1 | +11,250 | $45.28 | $509k | 41,811 | Dec 9, 2024 |
| Dec 9, 2024 | SOpen-market sale Common Stock10b5-1 | -11,250 | $71.68 | $806k | 30,561 | Dec 9, 2024 |
| Dec 9, 2024 | MOption exercise Employee Stock Option (Right to Acquire)derivative10b5-1 | -11,250 | $0.00 | $0 | 45,000 | Dec 9, 2024 |
Related signals
Other insiders at Edwards Lifesciences Corp and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 7Weak | sell 510b5-1 | EW Edwards Lifesciences Corp | Lippis Daniel J. CVP, JAPAC | $185k | 2,500 | |
| 10Weak | sell 510b5-1 | EW Edwards Lifesciences Corp | BOBO DONALD E JR CVP,Strategy/Corp Development | $359k | 5,000 | |
| 41Moderate | sell 5 | EW Edwards Lifesciences Corp | Chopra Daveen CVP, TMTT | $128k | 1,750 | |
| 36Weak | sell 5 | EW Edwards Lifesciences Corp | Markowitz Wayne GM & SVP, Surgical | $43k | 583 | |
| 3Weak | sell 210b5-1 | EW Edwards Lifesciences Corp | BOBO DONALD E JR CVP,Strategy/Corp Development | $328k | 5,000 | |
| 38Weak | sell 210b5-1 | EW Edwards Lifesciences Corp | Wood Larry L Global President TAVR & Surg | $1.6M | 25,000 | |
| 0Weak | sell10b5-1 | EW Edwards Lifesciences Corp | BOBO DONALD E JR CVP,Strategy/Corp Development | $348k | 5,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.